Overview
Gait Evaluation in Multiple Sclerosis Patients Treated With Glatiramer Acetate
Status:
Unknown status
Unknown status
Trial end date:
1969-12-31
1969-12-31
Target enrollment:
0
0
Participant gender:
All
All
Summary
Hypothesis: Treatment with Glatiramer acetate prevents deterioration of gait in multiple sclerosis (MS) patients. During the study patients will undergo a 3 dimensional gait analysis before starting treatment with glatiramer acetate and after 1 year of treatment.Phase:
N/AAccepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Sheba Medical CenterTreatments:
(T,G)-A-L
Glatiramer Acetate
Criteria
Inclusion Criteria:- Clinical diagnosis of multiple sclerosis
- EDSS less than 5.5
- No cognitive disability
Exclusion Criteria:
- EDSS over 5.5
- Inability to cooperate with gait analysis